filmov
tv
Resistance to Targeted-TKI Treatment in Patients With CML

Показать описание
Difference between primary and secondary resistance attributing 50% of secondary resistance to mutations and use of ponatinib in T315I mutation.
Resistance to Targeted-TKI Treatment in Patients With CML
Mechanisms of TKI resistance
Resistance to TKI Therapies in GIST
ALK TKI Side Effects and Acquired Resistance - 2022 Program: Targeted Therapies Forum
Mechanisms of Resistance to EGFR TKI and New Treatment Strategies
Targeted treatment with EGFR TKIs: Front line options
Dr Pritam Kataria - Mechanism Of Resistance To KRAS TKI And Therapy Post Resistance
Understanding the cause of TKI resistance to improve management strategies in CML
The role of CML stem cells in relapse after TKI discontinuation & resistance to treatment
Treatment Resistance Due to Gene Mutation
EGFR TKI Resistance: Progress and Challenges
Mechanisms of Resistance to TKI in NSCLC
CRSF 7th Masterclass | Resistance to RET TKI & Post-Resistance Therapy by Dr. Vibhor Sharma
What is Acquired Resistance to Targeted Therapy, and Why Does it Occur?
EGFR TKI Resistance: Targeting MET Amplification
New target for treatment resistance after EGFR inhibitors found in lung cancer study
TKI Resistance: More than just Abl mutations
Emerging Agents and Combinations to Treat RET Fusion-Positive Lung Cancers
Acquired EGFR resistance: What are the current therapeutic strategies?
Tyrosine Kinase Inhibitors (TKIs) - Imatinib (Gleevec) - Pharmacology - CML and ALL
TRK Inhibition: Overcoming Acquired Resistances
Mechanisms of Resistance to Upfront EGFR-Targeted Therapy
2023 Best of Lung: Targeted Therapies in Lung Cancer
Acquired Resistance to Osimertinib in EGFR+ NSCLC - 2022 Program: Targeted Therapies Forum - English
Комментарии